Beauty Queen humiliated as crown ripped from her head on stage. SOURCE: Colombo Gazette
The "Global Needle Coke Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
The National Pest Management Association is sharing what Americans need to know if you live in a state affected by the emergence of Brood X cicadas.
Bowman is pleased to announce that Paul Kovacs, PE is joining Bowman as a principal, civil engineer, and key leader for the Lisle and Chicago, IL offices. He will play an integral role in providing insights into prospective clients’ needs and expectations, building partnerships with other project stakeholders, and developing successful strategies for Bowman’s pursuit of infrastructure projects, not only in the Chicago area, but nationwide.
(Bloomberg) -- Pfizer Inc. and BioNTech SE expect to deliver more vaccines to the European Union this quarter than currently targeted, offering good news to the bloc after deliveries of Johnson & Johnson’s shot were paused.Denmark became the first EU country to drop AstraZeneca Plc’s vaccine from its pandemic inoculation program, reflecting the same concerns over blood clots that prompted the J&J pause. Russia said there have been no cases of clotting with its Sputnik vaccine.South Africa said drugmakers including J&J demanded “unreasonable terms” in exchange for vaccine supplies. Germany’s rate of infections climbed further beyond a key threshold, and EU governments reached a deal on technical standards for so-called vaccine passports.Key Developments:Global Tracker: Cases pass 137 million; deaths exceed 2.96 millionVaccine Tracker: More than 814 million shots given worldwideVaccine givers at an Atlantic City convention hall race timeBlood Clots, anaphylaxis and other vaccine fears: QuickTakeWhat we know about the impact of Covid-19 on childrenWhich vaccine is best, and other questions answered (Video)Subscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click CVID on the terminal for global data on cases and deaths.Astra Shot Safe, Effective, Health Canada Says (11:40 a.m. NY)AstraZeneca’s vaccine may be linked to “very rare events of blood clots,” but the benefits of the shot outweigh its potential risk, Health Canada said in a statement following an assessment of scientific data.The federal agency has updated warnings about the possible side effects in product information and is providing information about potential symptoms as well as when to seek prompt medical attention following vaccination.J&J Drops Pregnant Women From Study (11:39 a.m. NY)Johnson & Johnson will revise protocols on its Covid-19 vaccine study and exclude pregnant health workers from a trial in South Africa set to include 500,000 people. The move came after U.S. regulators paused the shot’s rollout on concerns of a rare and severe blood-clotting side effect.While all studies are delayed, plans to run trials on children and pregnant women in South Africa have been set aside for now, said Glenda Gray, the co-lead of the South African studies, in an interview on Wednesday.The research team will meet with South African regulators later on Wednesday, she said. Airline Middle Seats Cited as Risk (11:38 a.m. NY)The risk of being exposed to the Covid-19 virus on an airline flight drop by as much as half when airlines keep middle seats open, a new study published by the U.S. government concludes, a safety practice the carriers have abandoned.The study is the latest to roil the waters on a controversial topic: just how risky it is to travel during the pandemic. It didn’t attempt to estimate infection risks and was based on modeling done before the pandemic, so it didn’t consider rules that now require face masks on flights.The risk of coming in contact with the virus dropped by 23% to 57% if airlines limited passenger loads on both single-aisle and widebody jets, compared with full occupancy, according to research released by the Centers for Disease Control and Prevention on Wednesday.U.S. Spy Chiefs Say Virus Source Unknown (11:25 a.m. NY)U.S. spy agencies have yet to determine the source of the virus that causes Covid-19, top intelligence officials told the Senate Intelligence Committee Wednesday.Avril Haines, the director of National Intelligence, said analysts are still examining two theories: animal-to-human transmission, and the possibility of a laboratory accident. “The intelligence community does not know exactly where, when or how Covid-19 virus was transmitted initially,” Haines said.CIA Director William Burns, echoed Haines’ assessment, adding that “the Chinese leadership has not been fully forthcoming or fully transparent” in working with the World Health Organization to pinpoint the origin of the coronavirus.The spy chiefs’ assessments add to a growing number of top politicians and public health experts who argue that the theory of a lab leak warrants further investigation. In late March, WHO Director-General Tedros Adhanom Ghebreyesus said a mission to study the origins of the virus was too quick to dismiss the theory of a lab leak.Russia Says No Clotting Cases From Sputnik (10:45 a.m. NY)The developers of Russia’s Sputnik V vaccine said it hasn’t produced any instances of the dangerous blood-clotting that forced U.S. officials to urge a pause in the use of Johnson & Johnson’s vaccine.Sputnik’s first dose uses the same human adenovirus as the Johnson & Johnson inoculation, but they have “significant differences in their structure” and it isn’t appropriate to extrapolate safety data from one to the other, the state-run Gamaleya Center said in a statement.Switzerland Allows Theaters to Open (10:45 a.m. NY)Switzerland will allow theaters, cinemas and outdoor dining at restaurants to open starting Monday, pursuing once again a more liberal course than many of its European neighbors.While facilities will be subject to capacity limitations, the move stands in contrast to France, where officials have responded to an increase in Covid-19 infections by doubling down on restrictions.Outdoor events will be limited to 100 people, while indoors at cinemas or concerts the maximum is 50.EU Sees J&J Recommendation Next Week (9:43 a.m. NY)The European Union’s drug regulator is accelerating its review of blood-clot reports with J&J’s vaccine and said it expects to issue a recommendation next week.EU member states should store doses as they await guidance, and the European Medicines Agency said it will decide shortly whether “regulatory action is necessary.”Astra Shot Induces Strong T-Cell Response (9:40 a.m. NY)The Astra vaccine generated a stronger cellular immune response than the Pfizer and BioNTech shot in people over 80 years old, a study by U.K. researchers shows.Responses in T cells -- a type of white blood cell that helps fight viruses -- were seen in 31% of participants receiving the Astra vaccine and 12% of the Pfizer-BioNTech group, according to the University of Birmingham and U.K. Coronavirus Immunology Consortium. Elderly people receiving a single dose of either vaccine showed equivalent antibody responses after five weeks.It’s unclear if the different levels of T cell responses observed will have any impact on clinical effectiveness, the researchers said.NYC Reschedules 4,000 Appointments (9:29 a.m. NY)New York City had to reschedule 4,000 shots on Tuesday due to the Johnson & Johnson pause, according to Health Commissioner Dave Chokshi. The “vast majority” of New Yorkers will keep the same appointments but receive the Pfizer or Moderna shots instead.The city’s homebound senior vaccine program, which depended on the J&J shot, will be suspended through Sunday, but the city is working to reschedule appointments and arrange transports by taxi or ambulette, Chokshi said.Denmark Is First in EU to Drop Astra Shot (8:14 a.m. NY)Denmark has become the first country in the European Union to drop AstraZeneca Plc’s vaccine from its inoculation program amid concerns over blood clots.Denmark was one of the first countries to suspend the vaccine, on March 11. At the time, the Danish Health Authority called the decision a precautionary move and reiterated its view that Astra’s vaccine was “effective and safe.”Pfizer to Speed EU Deliveries (7:42 a.m. NY)Pfizer Inc. and BioNTech SE will raise Covid-19 vaccine deliveries to the European Union by 50 million this quarter, offering good news to the bloc after Johnson & Johnson’s shot was paused.The drugmakers will bring forward deliveries scheduled for the fourth quarter, European Commission President Ursula von der Leyen said Wednesday. The additional supplies will add to the 200 million doses the EU was already expecting from Pfizer through June. The company provided about 66 million in the first three months of the year.EU Vaccine Passports Draw Closer (7:30 a.m. NY)European Union governments reached a deal on technical standards for so-called vaccine passports, advancing the effort to boost travel to and within the bloc in time for the summer season.Envoys meeting in Brussels unanimously supported a draft legal text setting out specifics for “digital green certificates,” according to a diplomat familiar with the private meeting. The documents will provide proof their holders have been vaccinated against the coronavirus, tested negative or have recently recovered from the disease and are considered immune.India to Get 250 Million Sputnik Doses (5:09 p.m. HK)Sputnik V’s capacity in India should be “ramped up significantly” in the next quarter, said Dr. Reddy’s Laboratories’s chief executive for API and Services Deepak Sapra.Initially, the vaccines will be imported from Russia and distributed by Dr. Reddy’s, according to Sapra. Eventually, six manufacturers in India are lined up to make the shot.Poland Extends Most Virus Restrictions (4:54 p.m. HK)Poland will reopen nurseries and kindergartens as of Monday but extend other restrictions that were due to end after April 18, Health Minister Adam Niedzielski said.S. Africa Says J&J Seeks Unreasonable Terms (4:13 p.m. HK)South Africa is facing delays to vaccine supplies because of “unreasonable terms” being demanded by manufacturers including Johnson & Johnson, Health Minister Zweli Mkhize said.J&J won’t sign off on 20 million doses until the company gets a letter from the trade and industry minister expressing support for its investment in local drugmaker Aspen, Mkhize told lawmakers.Denmark to Reopen Borders for Some Countries (2:26 p.m. HK)Denmark will gradually reopen its borders to some countries next month when older Danes are expected to have gotten at least one dose of vaccine, the government said.Denmark will be open to vaccinated citizens from European countries as of May 1. Residents who haven’t gotten a shot but come from European countries with low contamination rates will be able to enter Denmark from May 14. Travelers will need to provide a recent negative test and isolate upon arrival, unless they have been vaccinated.EasyJet Hangs on to Summer-Revival Hopes (2:22 p.m.)EasyJet Plc said it remains optimistic that European travel markets will be revived this summer even as vaccination campaigns and plans to reopen borders stutter.The London-based carrier will operate no more than 20% of 2019 capacity in the three months through June but said in a statement Wednesday that it’s ready to ramp up flights from May if there’s sufficient demand.Taiwan to Expand Covid Shots (2:12 p.m. HK)The government will provide 10,000 doses of vaccines for people who are traveling abroad from April 21, according to Taiwan’s Centers for Disease Control. Taiwan started to vaccinate healthcare workers from last month.German Incidence Rate Hits Three-Month High (1:37 p.m. HK)Germany’s infection rate climbed further beyond a key threshold, a day after the government approved legislation that mandates tougher restrictions in virus hotspots.The seven-day rate of cases per 100,000 people rose to 153.2, the most since Jan. 13, the RKI public-health agency said on its website.Chancellor Angela Merkel urged lawmakers in both houses of parliament to support the legislation, which triggers stricter curbs when the incidence rate climbs above 100.CanSino Finds No Severe Side Effects (1:29 p.m. HK)CanSino Biologics Inc said it hasn’t found any severe side effects such as blood clots after about 1 million vaccinations with its shot, which relies on the same approach as AstraZeneca Plc’s and Johnson & Johnson’s.The Astra, J&J and CanSino vaccines, as well as Russia’s Sputnik V, all uses an adenovirus to deliver the genetic material into the body to provoke a defense against Covid-19.France Prepares to Reopen Businesses (1:28 p.m. HK)President Emmanuel Macron will meet Thursday with ministers to prepare the rules for reopening French businesses next month.Macron said in March that bars and restaurants would be back in business in mid-May with outdoor seating, and that cultural establishments also would reopen.The country is eyeing a restart even as it prepares to cross the threshold of 100,000 deaths from Covid-19.Asian Countries Take a Look at J&J Shots (12:28 p.m. HK)Regulators in New Zealand are slated to make a decision Thursday on Johnson & Johnson’s vaccine. The Philippines expects to sign with the company this week, while Thailand approved the shot for emergency use on March 25. India, facing a mounting outbreak, has said it will fast-track approvals of vaccines cleared in other countries -- including the one from J&J.South Korea, which granted the company conditional approval last week and has placed the largest order in the region for it, said it will monitor the U.S. suspension and track the shot’s safety. It isn’t expecting shipments until the third quarter. Japan also said it’s gathering information.Indonesia is considering vaccines developed by J&J and other drugmakers to boost its arsenal, according to Health Ministry spokesperson Siti Nadia Tarmizi.India Records Daily Record of New Cases (12:25 p.m. HK)India reported another record daily tally of cases, adding more than 184,000 overnight to push its total number of infections to more than 13.8 million, second only to the U.S. The capital, New Delhi, also reported a record surge.The nation’s crematoriums and burial grounds are working overtime to cope with the surging number of deaths and hospitals report being swamped with cases. The escalating public-health crisis highlights just how ill-prepared Prime Minister Narendra Modi’s administration has been to deal with this second wave.Philippines May Miss Growth Target (11:53 a.m. HK)The Philippines may miss its target of at least 6.5% economic growth this year after a virus resurgence forced the capital into a two-week lockdown, Economic Planning Secretary Karl Chua said.“We were a healthy economy before Covid. Now, we’re struggling,” Chua said in an interview Tuesday. “We were too risk averse: We shut down a big part of the economy when other countries didn’t need to do that.”Sinopharm Shots Show No Severe Side Effects (11:46 a.m. HK)More than 100 million doses of two inactivated vaccines developed by Sinopharm’s China National Biotec Group have been administered so far, the company says on its WeChat account.Jakarta Extends Inoculations to General Public (9:01 a.m. HK)The Indonesian capital is extending its vaccination drive to the general public by allowing those accompanying the elderly to also get an injection, according to the provincial government.The initiative should allow Jakarta to achieve its goal of vaccinating over 900,000 people, the government said. Each person between 18 and 59 accompanying two people aged 60 and over will also be eligible to receive their first dose.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
(Bloomberg) -- Wells Fargo & Co. jumped the most in almost two months after profit soared sevenfold, giving scandal-weary investors something to cheer as Chief Executive Officer Charlie Scharf’s turnaround effort shows signs of progress.Shares of the company advanced 5.2% after the first-quarter earnings report and comments from Scharf, who said the company is anxious to raise its “quite low” dividend.Scharf, who took over in late 2019, has focused on streamlining operations and pledged to eventually shave $10 billion off annual expenses. The firm announced sales of its asset manager and corporate-trust unit in the first quarter, and said in January that its rail-leasing unit is on the chopping block too. Wells Fargo has said it has more than 250 expense initiatives in the works that will take three to four years.“We’re in the midst of a multiyear transformation, and I’m confident that our operational and financial performance will continue to benefit from the progress we’re making,” Scharf said on a conference call with analysts.U.S. lenders are also benefiting from the government’s massive stimulus efforts and an economic rebound that’s kept the worst of the predicted pandemic fallout from materializing. That should continue to boost net interest income, one of the bank’s main sources of revenue, according to Chief Financial Officer Mike Santomassimo. He also said the bank expects additional loan-loss reserve releases if the economy continued on its current trajectory.First-quarter net income at the San Francisco-based bank rose to $4.74 billion, boosted by a larger-than-expected release of loan-loss reserves, according to a statement Wednesday. Non-interest expenses were $14 billion, up from a year earlier and a touch higher than analysts forecast, while net interest income was lower than expected.The first-quarter results “reflected an improving U.S. economy, continued focus on our strategic priorities, and ongoing support for our customers and our communities,” Scharf said in the statement. “Charge-offs are at historic lows and we are making changes to improve our operations and efficiency, but low interest rates and tepid loan demand continued to be a headwind for us in the quarter.”Wells Fargo shares climbed to $41.86 at 1:24 p.m. in New York, the biggest increase on an intraday basis since Feb. 17 and the largest increase on the 24-company KBW Bank Index. JPMorgan Chase & Co., which also reported first-quarter earnings Wednesday, was down 1.2%.Wells Fargo remains under costly Federal Reserve-imposed restrictions that limit assets to their level at the end of 2017. In one of the first signs of success in the drive to escape the penalty, the company secured the Fed’s acceptance of a proposal it submitted last year.The firm is working to complete the next steps needed to lift the punishment: adopting the plan and undergoing an independent review. Bloomberg reported in December that a number of top executives privately expect Wells Fargo won’t escape the asset cap before late this year, while key Fed officials see the process dragging into 2022 or beyond.“Our work to build the appropriate risk and control environment remains our top priority,” Scharf said in the statement. “This is a multiyear effort and there is still much to do, but I am confident we are making progress, though it is not always a straight line.”Scharf also elaborated on the firm’s growth opportunities, saying Wells Fargo is working on its credit-card offerings and going after middle-market investment banking “in a different way than we have previously.”“We’re under-penetrated in credit card given our customer footprint, and we’re working on developing a significantly improved value proposition that we can introduce to the market,” Scharf said.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The "Construction in India - Key Trends and Opportunities to 2025 (Q1 2021)" report has been added to ResearchAndMarkets.com's offering.
The equity stake won't cost Future FinTech much. But it's providing a lot of cash to fund growth.
LEAD PLAINTIFF DEADLINE IS JUNE 9, 2021NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of purchasers of the securities of Champignon Brands Inc. (OTC: SHRMF) between March 27, 2020 and February 17, 2021, inclusive (the "Class Period"). All investors who purchased shares of Champignon Brands Inc. and incurred losses are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.whafh.com. If you have incurred losses in your investment in Champignon Brands Inc., you may, no later than June 9, 2021, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of Champignon Brands Inc. CLICK HERE TO JOIN CASE According to the filed complaint, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Champignon had undisclosed material weaknesses and insufficient financial controls; Champignon's previously issued financial statements were false and unreliable;Champignon's earlier reported financial statements would need to be restated; Champignon's acquisitions involved an undisclosed related party;as a result of the foregoing and subsequent reporting delays and issues, the British Columbia Securities Commission would suspend Champignon's from trading; and as a result, defendants' statements about Champignon's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation. If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website. Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq.Gregory Stone, Director of Case and Financial AnalysisEmail: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.comTel: (800) 575-0735 or (212) 545-4774 This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Data in Animal Model of PAH Demonstrate Ability of R-107 to Durably Reverse Established DiseaseSAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into a binding Letter of Intent (the “LOI”) with Salzman Group, Inc. (a Delaware corporation), Salzman Group, Ltd. (an Israeli corporation), and Salzman Group Pty. Ltd. (an Australian corporation), (collectively, the “Salzman Group”), under which Salzman Group will grant to Claritas an exclusive, worldwide license to develop and commercialize R-107 for the treatment of pulmonary arterial hypertension (“PAH”). The Company expects that definitive agreements will be executed by May 15, 2021. Closing of the transaction is subject to receipt of all regulatory approvals, including approval of the TSX Venture Exchange. Highlights Claritas is developing R-107 for the treatment of viral infections, and will now also develop R-107 for the treatment of PAH.PAH is a lethal condition, resulting from high blood pressure in the lungs.The worldwide market for treatment of PAH exceeds $6 billion per year and is projected to grow to $9.8 billion by 2027.R-107 is the first and only agent to demonstrate a durable reversal of established disease in a validated animal model of PAH.Claritas’ development strategy for R-107 in PAH is designed to expedite the potential monetization of this asset. R-107 is a Nitric Oxide-Releasing Compound R-107 is a liquid, nitric oxide-releasing compound with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea. Claritas initially licensed R-107 from Salzman Group for the treatment of COVID-19 and other viral infections. Claritas and Salzman Group will now enter into a separate License Agreement under which Salzman Group will grant to Claritas exclusive, worldwide rights to develop R-107 for the treatment of PAH. Claritas Will Develop R-107 as a Nitric Oxide Therapy for Treatment of Both Viral Infections and PAH “R-107 is a platform technology that transforms nitric oxide therapy from an impractical, expensive, and difficult to administer inhalation therapy, into a practical treatment that can simply be administered by capsule, injection, or nasal spray,” stated Robert Farrell, Claritas’ President and CEO. “It has been demonstrated that nitric oxide is a potent antiviral therapy, and for this reason, we are already developing R-107 as a nitric oxide therapy for treatment and prevention of coronavirus, vaccine-resistant COVID-19 infection, influenza, and the common cold. It has also been demonstrated that nitric oxide is clinically effective in the treatment of PAH.1 For this reason, we are now acquiring exclusive, worldwide rights to develop R-107 as a nitric oxide therapy for PAH.” Mr. Farrell went on to say, “R-107 was evaluated in the same animal model of PAH in which the currently approved drugs for PAH were also tested. The results of this study were exceptional. R-107 was observed to be superior to all of the approved drugs in reducing pulmonary arterial blood pressure. R-107 was also seen to durably reverse disease severity after a short course of therapy. R-107 is the first and only drug to demonstrate the ability to reverse established disease. Based on these exceptionally positive and unique findings, we believe that R-107 could become a best-in-class, front-line therapy for PAH. If we can demonstrate similar data with R-107 in a Phase 2 clinical study in humans, we believe that R-107 will be viewed as a potentially valuable pharmaceutical asset that we might seek to out-license or sell. We will initiate and complete our Phase 1 clinical study this year, and we expect to complete a Phase 2 study of R-107 in the treatment of PAH in 2022.” “With the addition of R-107 for treatment of PAH, Claritas will now have a two programs addressing large commercial markets. We are currently developing R-107 for treatment of viral infections, including vaccine-resistant COVID-19 infection, and now we will also have a potential breakthrough product that could provide unrivalled results in treatment of PAH.” R-107 is Designed to Unlock the Potential of Nitric Oxide Therapy Claritas is focusing on the therapeutic potential of nitric oxide because it is known to be safe and effective in the treatment of many diseases and disorders. In 1992, Science magazine named nitric oxide molecule of the year; more than 130,000 peer reviewed articles have been published on nitric oxide; and nitric oxide was the subject of a 1998 Nobel Prize in medicine. Claritas’ approach is to supplement the body’s natural nitric oxide with supplemental nitric oxide that will be delivered by the Company’s liquid, nitric oxide-releasing drug, R-107. R-107 has several advantages over inhalable nitric oxide gas: Inhalable nitric oxide gas that is administered by inhalation therapy is quickly metabolized in the body, with a half-life of only 2-6 seconds. In contrast, R-107 delivers constant, sustained, therapeutic levels of nitric oxide throughout the body over a 24-hour period.Inhalable nitric oxide can only reach areas of the lungs with excellent ventilation. In patients with PAH, there are sections of the lungs that are poorly ventilated, which inhaled nitric oxide cannot reach. By contrast, R-107 delivers nitric oxide systemically, throughout the body and throughout the lungs, including areas of the lungs that are poorly ventilated.Inhalable nitric oxide gas is expensive and difficult to administer, requiring the use of specialized gas delivery systems that must be managed by trained respiratory therapists. In contrast, R-107 can simply and inexpensively be administered by injection or orally by capsule. Pulmonary Arterial Hypertension (“PAH”) PAH is a critical unmet medical need, presenting both as an acute condition in critically ill hospitalized patients and as a chronic disease managed on an out-patient basis. PAH is characterized by profound elevations in blood pressure that selectively present in the arteries of the lungs, without effect on systemic blood vessels so that peripheral blood pressure is normal. It is a serious condition that makes it difficult for blood to flow through the lungs, which, in turn, forces the right side of the heart to work harder than normal. In its acute manifestation, life-threatening PAH may appear abruptly, such as after an acute pulmonary embolus or in the perioperative setting following cardiac valve replacement. In the chronic setting, PAH is a progressive disease that limits physical activity and ultimately results in right heart failure and death, typically taking place within five years after the initial presentation of symptoms. There is currently no cure for PAH, although there are several approved drugs that can transiently ease the symptoms of the disease and slow its inexorable progression. No marketed agents nor drugs in development however have been shown to durably reverse disease severity. Moreover, all of the currently approved drugs exhibit significant side-effects that limit their acceptability and negatively impact quality of life. Despite the major shortcomings of existing pharmaceutical agents, the current market for such drugs exceeds $6 billion per year, and the market is projected to grow to $9.8 billion per year by 2027.2 R-107 is a Potentially Revolutionary New Treatment for PAH R-107 was tested in a classic and well-validated animal model of PAH, induced by administration of monocrotaline (“MCT”) to rats. The data from this study were exceptionally positive. In an acute setting, a single dose of R-107 was able to reverse severe pulmonary arterial hypertension back to a normal level of blood pressure for more than 24 hours, constituting a profound correction that is unprecedented in the scientific literature. In a chronic setting, daily administration of R-107 was able to entirely prevent the increase in pulmonary arterial blood pressure that triples in untreated animals exposed to MCT. Most importantly, a 2-week course of daily R-107 initiated 28 days after the onset of MCT-induced PAH surprisingly showed a 50% reduction in pulmonary blood pressure that persisted after the cessation of the course of R-107 therapy. This durable amelioration of PAH, which constituted a true reversal of disease severity, has not been heretofore witnessed in this gold-standard PAH model system and represents therefore a potential paradigm shift in the management of PAH. Up to now, the objective of clinical PAH therapies is to slow progression of a terminal disease. These new data, evidencing a reversal of disease severity, are qualitatively different and will allow the company to focus on a fundamental correction of underlying disease. By comparison, in this same animal model, the currently approved drugs for PAH have been shown to slow the progression of the disease, but not the ability to completely block its progression nor to durably reverse disease severity. R-107 is in fact the first and only agent known to demonstrate a durable reversal of disease severity in the MCT-induced rodent model of PAH. Claritas’ Development Plan for R-107 in PAH is Designed to Expedite the Monetization of this Asset by Year-End 2022. Claritas expects to complete a Phase 1 clinical study of R-107 in 2021, and to complete a pilot Phase 2 clinical study of R-107 in hospitalized patients in 2022. R-107 in the injectable formulation will be initially evaluated in a Phase 1a single ascending dose escalation study in healthy volunteers at CMAX in Adelaide, Australia this year. Thereafter, a Phase 2a study will evaluate 12 patients with chronic PAH undergoing route cardiac catheterization. The Phase 2a clinical study of R-107 will be conducted at Royal Adelaide Hospital in Adelaide, Australia in order to establish proof-of-concept that the reduction in blood pressure is restricted to the pulmonary circulation, without a concomitant impact on peripheral hemodynamics. Due to the short period of observation of each study participant (24 hours) and the relatively small number of patients under examination, the Company believes that the Phase 2a clinical trial may be readily conducted at a single site and completed within several months. Demonstration of proof-of-concept could provide the scientific foundation for an immediate sale or strategic out-licensing of R-107 on highly favorable terms. If Claritas is able to demonstrate a selective reduction in blood pressure of a magnitude similar to what was demonstrated in the MCT-induced rodent model of the disease, the Company believes that R-107 will be viewed as a significantly valuable pharmaceutical asset, given that achievement of the Phase 2a clinical trial endpoints should constitute a major inflection point in the value of the technology. Speaking at a press conference today in San Francisco, Claritas’ CEO Mr. Robert Farrell commented that, “We are thrilled to acquire the rights to R-107 for treatment of PAH. This liquid nitric oxide donor has demonstrated extraordinary efficacy in a gold-standard animal model and thus is viewed by our team as a potential medical breakthrough opportunity in the field, targeting an orphan drug indication that is already established as a very significant global commercial opportunity. The Company will move forward aggressively to implement its development plan, advancing R-107 into a Phase 1 clinical safety trial in 2021 followed by a definitive proof-of-concept Phase 2a study to be completed next year.” Terms of the LOI The LOI which Claritas has entered into with the Salzman Group provides that which Salzman Group will grant to Claritas an exclusive, worldwide license to develop and commercialize R-107 for the treatment of PAH (the “PAH License”). Under the terms of the LOI, Claritas has agreed to provide the following compensation to Salzman Group in consideration for the PAH License: Upon execution of the definitive PAH License Agreement, Claritas will issue 26 million shares of Claritas’ common stock to Salzman Group, Inc. Provided, however, that Claritas will not issue any common shares to Salzman Group, Inc. unless Salzman Group, Inc. and all affiliates certify that the issuance of such common shares will not cause Salzman Group, Inc. and its affiliates to beneficially own in excess of 19.99% of the Company’s outstanding shares of common stock;Claritas will pay cash license fees of USD $12,300 to Salzman Group Pty. Ltd. and USD $287,70 to Salzman Group Ltd. within 90 days of the execution of the definitive PAH License Agreement;Claritas will also pay the following cash milestone payments and royalties on net sales to Salzman Group, Inc. Pulmonary Hypertension Milestones & Royalties: USD $2 million on completion of Phase 3 registration study in the PAH indicationUSD $2 million on submission of NDA to FDA in PAH indicationUSD $5 million on FDA approval for the PAH indicationUSD $5 million on EMEA approval for the PAH indicationUSD $5 million on Japanese approval for the PAH indicationDuring the applicable term of any patent covering R-107 in the treatment of PAH, Claritas will pay to Salzman Group, Inc. a royalty of eight percent (8%) of the net sales for all R-107 products for the treatment of PAH About Claritas PharmaceuticalsClaritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas leverages its expertise to find solutions that will improve health outcomes and dramatically improve people's lives. Website Home: https://claritaspharma.com/News and Insights: https://claritaspharma.com/news/Investors: https://claritaspharma.com/investors Cautionary StatementsNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives, and other statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that future clinical studies may not proceed as expected or may produce unfavorable results. Claritas undertakes no obligation to comment on analyses, expectations or statements made by third parties, its securities, or financial or operating results (as applicable). Although Claritas believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Claritas’ control. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Claritas disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Contact InformationRobert FarrellPresident, CEO(888) 861-2008info@claritaspharma.com 1 Nitric Oxide and Pulmonary Arterial Hypertension, Glob Cardiol Sci Pract. 2017 Jun 30; 2017(2): 14.: Adrian H. Chester, Magdi H. Yacoub, and Salvador Moncada 2 Pulmonary Arterial Hypertension Market Size Worth $9.8 Billion By 2027, Grand View Research, February 2020
Rangers said Glen Kamara had been vindicated after UEFA banned Slavia Prague defender Ondrej Kudela for 10 European matches on Wednesday for racially abusing the Finnish midfielder in a Europa League match.
PLANO, Texas, April 14, 2021 (GLOBE NEWSWIRE) -- INTRUSION, Inc. (NASDAQ: INTZ), a leading provider of cyberattack prevention solutions including Zero-Days, intends to fully respond to unfounded claims made in a research report published this morning. Jack Blount, President and CEO of INTRUSION said, “A short report includes claims that are blatantly inaccurate and reflect a malicious short-selling agenda. The Company is evaluating further actions.” About INTRUSION, Inc. INTRUSION, Inc. (NASDAQ: INTZ) protects any-sized company by leveraging advanced threat intelligence with real-time artificial intelligence to kill cyberattacks as they occur – including zero-days. INTRUSION’s solution families include INTRUSION Shield, an advanced cyber-defense solution that kills cyberattacks in real-time using artificial intelligence (AI) and advanced cloud threat intelligence; INTRUSION TraceCop™ for identity discovery and disclosure; and INTRUSION Savant™ for network data mining and advanced persistent threat detection. For more information, please visit www.intrusion.com. Cautionary Statement Regarding Forward Looking Information This release may contain certain forward-looking statements, which reflect management's expectations regarding future events and operating performance and speak only as of the date hereof. These forward- looking statements involve a number of risks and uncertainties. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, including, risks that we have detailed in the Company's most recent reports on Form 10-K and Form 10-Q, particularly under the heading “Risk Factors.” CONTACT: IR Contact Joel Achramowicz jachramowicz@sheltongroup.com P: 415-845-9964
Shares of Wells Fargo (NYSE: WFC) were up a little over 5% at 1:39 p.m. EDT on Wednesday after the financial services giant topped earnings estimates and said its turnaround is progressing according to plan.
A US Capitol police officer has been cleared of any wrongdoing in the fatal shooting of Air Force veteran Ashli Babbitt during the 6 January riot. Ms Babbitt was shot as she attempted to beach a barricaded doorway inside the Capitol as pro-Trump rioters stormed Congress. Federal prosecutors in Washington, DC made the decision saying that there was insufficient evidence to prove that Ms Babbitt’s civil rights were violated.
Please send your letters to letters@independent.co.uk
PepsiCo Inc's results on Thursday will give investors a glimpse of how widespread vaccinations impacted snack sales at the soda giant. "We would expect the majority of investor focus to be less around the quarter and more likely pacing for the rest of the year," J.P.Morgan analyst Andrea Teixeira said. "A lot of people are really underestimating the potential for millions of people working from home ... This increases number of food occasion at home, especially breakfast and snacking, which is right in PepsiCo's wheelhouse," Edward Jones analyst John Boylan said.
COINBASE, the San Franciso-based cryptocurrency exchange, gatecrashed the top 100 biggest US companies today as shares rocketed 52% in value on its Wall Street debut. Going on sale via a direct listing rather than a traditional float - the biggest company so far to take this route to market on the Nasdaq - shares pegged at the estimated reference price of $250 started changing hands at $381. Today is a big milestone for Coinbase and an even bigger milestone for crypto.
Full-time associates will receive consistent schedules with 39 to 40 hours per week.
Erling Haaland will hope to end his barren run in front of goal when Borussia Dortmund battle Manchester City in the Champions League tonight. Haaland, who is being chased by almost every top European side, has not scored in six games for club and country - his longest goalless drought since moving to the Bundesliga. Marco Reus's away goal may prove vital against City, but he may not be fit for the quarter-final return leg along with Mats Hummels with Dortmund trailing 2-1.
The former Bachelor publicly came out as gay on Good Morning America
The "Asia Pacific Electronic Clinical Outcome Assessment Market By Delivery Mode, By End Use, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
Yahoo Finance